Ncardia has launched a panel of ready-to-use cell-based assays to simplify the screening and selection of treatment candidates for neurodegenerative diseases, including Parkinson’s disease. The assays are based on human-derived induced pluripotent stem cells (iPSCs), a type of stem cell that can generate nearly all types of cells.
A newly developed biosensor that can rapidly detect and quantify levels of dopamine — a chemical messenger nerve cells use to communicate — may serve as a low-cost and efficient tool to diagnose and monitor people with Parkinson’s disease or other conditions marked by abnormal dopamine levels. Developed by…
Having difficulty recognizing and describing emotions may be associated with cognitive issues and with mood disorders such as depression, apathy, and impulse control problems in people with Parkinson’s disease, a review study suggests. As a result, the condition, called alexithymia, or emotional blindness, may reduce patients’ health-related quality of…
The U.S. Food and Drug Administration (FDA) has again cleared Rebrain’s OptimMRI software, this time including a new machine learning model to assist in targeting specific brain regions for lesioning techniques such as MR-guided focused ultrasound and radiosurgery. Lesioning techniques involve the destruction of small areas of abnormal brain…
The Parkinson’s Foundation said it awarded nearly $3 million in research grants to 33 recipients, aiming to accelerate innovative studies towards the development of potential new therapies, treatments, and ultimately a cure for Parkinson’s disease. “We are excited to fund these promising grant recipients as they develop more…
Women with current or past migraines were not seen to be at a higher risk of developing Parkinson’s disease in a recent study that analyzed data from a large U.S. clinical trial of women’s health. The risk was similar across the migraine types experienced by the women, including those with…
Enrollment is complete in a Phase 2 trial of VG081821, an investigational therapy to treat early to mid-stage Parkinson’s disease, the therapy’s developer, Vimgreen, announced. A total of 150 patients have been randomized to receive a low or high dose of VG081821 or a placebo for 12 weeks, or…
Ryan Reynolds is the face of an educational campaign aiming to raise awareness of lesser-known Parkinson’s disease symptoms: the hallucinations and delusions that can be related to the disease. The ‘More to Parkinson’s’ initiative, sponsored by Acadia Pharmaceuticals, features a six-part series in which the actor…
Sensor-equipped shoes — called NUSHU smart shoes — that are designed to support people with walking difficulties due to Parkinson’s disease and other neurological conditions have received the CE mark of approval in the Europe Union (EU). The shoes perform clinical-grade gait analysis in real time, with biofeedback given…
Photopharmics said the first 100 patients have been enrolled in a Phase 3 trial testing its light-based therapy device, Celeste, to treat Parkinson’s disease. The Light for PD trial, which is expected to enroll 300 patients, is evaluating the device’s safety and efficacy at easing both motor and…
Get regular updates to your inbox.